Abstract
Mean ratings of positive and negative symptoms and depression significantly improved in nine treatment-resistant schizophrenic patients who completed a 6-week open trial of fluoxetine added to their neuroleptics. The authors identify differences between responders and nonresponders and recommend controlled trials.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Antipsychotic Agents / therapeutic use*
-
Clinical Trials as Topic
-
Depression / drug therapy
-
Drug Therapy, Combination
-
Female
-
Fluoxetine / therapeutic use*
-
Humans
-
Male
-
Pilot Projects
-
Schizophrenia / drug therapy*
-
Schizophrenic Psychology
Substances
-
Antipsychotic Agents
-
Fluoxetine